Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura.
Fianchi
Luana
L
Rossi
Elena
E
Murri
Rita
R
De Stefano
Valerio
V
Pagano
Livio
L
Leone
Giuseppe
G
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000139:chemically induced* / Q000188:drug therapy / Q000382:microbiology; D001234:Aspergillus niger / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000935:Antifungal Agents; D007155:Immunologic Factors; D011743:Pyrimidines; D014230:Triazoles; D000069283:Rituximab; D065819:Voriconazole